Trial of Trastuzumab + ALpelisib +/- Fulvestrant vs Trastuzumab + Chemotherapy in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

• Status: Recruiting
• Trial end date: 2026-07-01

Summary

Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Spanish Breast Cancer Research Group
• Collaborators: Breast International Group; International Breast Cancer Study Group; Novartis Pharmaceuticals
• Treatments: Capecitabine; Fulvestrant; Trastuzumab; Vinorelbine